Tue, Sep 16, 2014, 4:03 AM EDT - U.S. Markets open in 5 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

stockmktgenius 5 posts  |  Last Activity: Sep 4, 2014 6:07 AM Member since: Oct 12, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • stockmktgenius stockmktgenius Sep 4, 2014 6:07 AM Flag

    http://finance.yahoo.com/echarts?s=ISIS+Interactive#symbol=ISIS;range=2y

  • stockmktgenius stockmktgenius Sep 4, 2014 6:07 AM Flag

    If you click on the Isis chart, then click on 2 years, then "Compare" and fill in "VICL" that'll tell you everything you need to know about how terrible dark's advice has been. Vical investors have gotten killed while Isis investors have gotten rich. Dark is paid by people who want to buy Isis cheap, so his job is to discourage you. Big waste of time to read him or his aliases. Go to investor village if you want to read something intelligent about Isis.

  • Reply to

    Why I'm Confident

    by stockmktgenius Aug 27, 2014 11:56 PM
    stockmktgenius stockmktgenius Aug 30, 2014 8:15 AM Flag

    This past week, Prohost Biotechnology, a respected evaluator of biotech companies and their products, predicted Isis will close 2014 at $60 and 2015 at $150 a share.

    BMO Capital had the following analysis: BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $70 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) after the company announced the initiation of a phase 3 study evaluating ISIS-APOCIII-Rx in patients with familial chylomicronemia syndrome (FCS).

    "High unmet need, unprecedented efficacy, and absence of competition provide a clear path to potential revenues of $600mm to $1B, with full rights retained by ISIS. Following approval on KYNAMRO and broad development of antisense therapeutics across 30+ indications, we believe that antisense therapeutics have been substantially validated with significant clinical and regulatory de-risking not reflected in current discounted valuation," the analyst said.

    The firm remains buyer of the stock saying only partial value is being attributed to 3 of 30+ programs and where upside potential from programs like FCS, SMA, TTR, FXI, high-risk diabetes and other orphan, neuromuscular and, metabolic programs is being ignored.
    -------
    You guys are so smart, why waste time here with dark and his basher aliases? Come to Investor Village. The level of conversation is night and day what you find here. And while you're at it, email Jetmanbash, one of our docs there, and ask to join our private Friends of Isis board, where you won't find dark or any of his creepy make-believe friends.

    Sentiment: Strong Buy

  • stockmktgenius by stockmktgenius Aug 28, 2014 12:01 AM Flag

    This, I think, is the best post I ever made on this site. It tells the truth about dark and the other paid bashers who've ruined this board.

    BASHERS HANDBOOK

    Bashers' Tactics from the Bashers Handbook
    1: Remember, BASHERS NEVER BASH A BAD STOCK.
    2: BASHERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES.
    3: BASHERS POST MANY TIMES A DAY.
    4: BASHERS WILL LIE TO YOUR FACE.
    5: BASHERS KNOW YOU CAN'T VERIFY THEIR STATEMENTS.
    6: BASHERS PLAY ON YOUR LACK OF KNOWLEDGE.
    7: BASHERS PLAY ON YOUR LACK OF PATIENCE.
    8: BASHERS BRING THE PRICE DOWN. That is the basher's job. The truth is not important. Lies are the norm. Post continuously on the board every day. They are trying to hit the newbies visiting the board. They are trying to wear out the longs on the board. They do whatever it takes to wear the longs out.

    How to deal with Bashers?

    IGNORE THEM FOLKS...how bashers are paid:

    When you REPLY to bashers you give them an opportunity to earn 5-7 bucks. A basher will attempt to milk three to five replies per post at one to two dollars each. This way the basher spreads negative influence to as many stockholders as possible. A basher will create this discussion thread because it takes less time reading more messages than is necessary. This ultimately allows the basher more time to post and make money.
    NEVER ENGAGE A BASHER; if you do so then YOU BECOME THE BASHER,S AID! Read the news, do your own homework and make your own decisions. Le

    Sentiment: Strong Buy

  • stockmktgenius by stockmktgenius Aug 27, 2014 11:56 PM Flag

    I don't go to this board anymore. Dark and his various aliases have polluted it with lies and nonsense. If you want a better board try investor village, though dark is there too under then name #$%$.

    On that board, I posted the reasons I'm confident Isis will be a huge success. Thought I'd share it here with you:

    A friend who has a small investment in Isis asked me why I'm so confident. This has caused me to clarify my thinking, and here's what I came up with:

    1. They've got 33 medicines (38 by year end), any 1 of which could cause the shares to multiply. Dr. Crooke says it's like if you've got 33 shots to make a basket- pretty likely you'll succeed. Most companies have just 1 or 2 medicines. When they're suggested to me, I always turn them down as if you've got 1 or 2 chances, that's a lot less than 33.

    2. They've got $600 million cash, so they're not going broke. Most biotechs are in money trouble.

    3. They have a revolutionary technology that absolutely works and, I believe will change the face of medicine, while incidentally making us fabulously wealthy. To learn more, why don't you put in a little time at their website.

    4.They've got the best pharmaceutical companies in the world as partners: Pfizer, Glaxo, Johnson & Johnson, etc. Last week, Biogen paid Isis $18 million. They wouldn't be partners with a company that wasn't top notch. 5. Almost all shares are owned by major institutions. Fidelity, for example, has shares worth $604 million. I bet they know what they're doing.

    Sentiment: Strong Buy

ISIS
38.84-2.45(-5.93%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
JDS Uniphase Corporation
NasdaqGSMon, Sep 15, 2014 4:15 PM EDT